Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

NCT00055809 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

NIH

Sponsor class

Conditions

Metastatic Gastrointestinal Carcinoid Tumor
Recurrent Gastrointestinal Carcinoid Tumor
Regional Gastrointestinal Carcinoid Tumor

Interventions

BIOLOGICAL: PEG-interferon alfa-2b
BIOLOGICAL: bevacizumab
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)